The glycoprotein IIb/IIIa inhibitor tirofiban (Aggrastat) is “non-inferior” to its more expensive counterpart abciximab (ReoPro) in ST-elevation MI patients undergoing percutaneous coronary intervention.
Canadian researchers have suggested previously that prevention of catheter thrombosis sometimes seen with the anticoagulant fondaparinux can be attenuated using standard doses of unfractionated heparin.